Le Lézard
Classified in: Health
Subject: SVY

Global Women's Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth


DUBLIN, Jan. 21, 2019 /PRNewswire/ --

The "Global Women's Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

"Global Women's Health Drugs Market to 2024" covers all indications within women's health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

The women's health market represents a small but growing therapy area. There are currently 277 pipeline products in active development for women's health, making it the 16th largest therapy area by pipeline size. Key indications within the area include endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia, menopausal disorders and infertility.

The global market is projected to grow at a compound annual growth rate (CAGR) of 5.16% till 2024. This relatively strong growth will be driven by a number of factors. These include the strong growth projected for human papillomavirus (HPV) vaccines, which are administered to girls and women in order to prevent development of CIN, an abnormality of the cells on the surface of the cervix, which can progress to cervical cancer in some cases.

The women's health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

Some 246 licensing deals have been completed within the women's health therapy area since 2006, demonstrating a relatively high level of activity, considering the small size of the therapy area. Co-development deal activity has been much lower, with only 78 deals completed since 2006.

The strategic consolidations landscape was largely dominated by small molecule products and products acting on G-protein coupled receptors (GPCR). The majority of deals identified were relatively low value although a small number of deals exceeded $500m in value, demonstrating that women's health products are capable of attracting high levels of investment.

Scope

Key Topics Covered:

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Therapy Area Overview
2.1.1 Endometriosis
2.1.2 Polycystic Ovarian Syndrome
2.1.3 Cervical Intraepithelial Neoplasia
2.1.4 Menopausal Disorders
2.1.5 Infertility
2.2 Symptoms
2.2.1 Endometriosis
2.2.2 Polycystic Ovarian Syndrome
2.2.3 Cervical Intraepithelial Neoplasia
2.2.4 Menopausal Disorders
2.2.5 Infertility
2.3 Diagnosis
2.3.1 Endometriosis
2.3.2 Polycystic Ovarian Syndrome
2.3.3 Cervical Intraepithelial Neoplasia
2.3.4 Menopausal Disorders
2.3.5 Infertility
2.4 Etiology and Epidemiology
2.4.1 Endometriosis
2.4.2 Polycystic Ovarian Syndrome
2.4.3 Cervical Intraepithelial Neoplasia
2.4.4 Menopause
2.4.5 Infertility
2.5 Pathophysiology
2.5.1 Endometriosis
2.5.2 Polycystic Ovarian Syndrome
2.5.3 Cervical Intraepithelial Neoplasia
2.6 Co-morbidities and Complications
2.6.1 Endometriosis
2.6.2 Polycystic Ovarian Syndrome
2.6.3 Cervical Intraepithelial Neoplasia
2.6.4 Menopause and Menopausal Disorders
2.6.5 Infertility
2.7 Treatment
2.7.1 Treatment Options

3 Key Marketed Products
3.1 Overview
3.2 Premarin family (conjugated estrogens) - Pfizer
3.3 Lupron/Lupron Depot (leuprolide acetate SR) - AbbVie
3.4 Gonal-F (follitropin alfa) - Merck KGaA
3.5 Mirena (levonorgestrel) - Bayer
3.6 Celebrex (celecoxib) - Pfizer
3.7 Implanon/Nexplanon (etonogestrel) - Merck & Co.
3.8 Yasmin/Yaz (drospirenone and ethinylestradiol) - Bayer
3.9 Nuvaring (ethinylestradiol and etonogestrel) - Merck & Co
3.10 Gardasil - Merck and Co
3.11 Esmya (ulipristal acetate) - Gedoen Richter/Allergan
3.12 Orilissa (elagolix sodium) - AbbVie

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials Landscape
4.4.1 Clinical Trial Failure Rates
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.4.4 Cumulative Clinical Trial Size
4.5 Assessment of Key Pipeline Products
4.5.1 Relugolix - Takeda Pharmaceutical Co. Ltd
4.5.2 Bremelanotide - AMAG Pharmaceuticals Inc
4.5.3 SAGE-217 - Sage Therapeutics Inc.
4.5.4 Fezolinetant - Ogeda SA
4.5.5 Zulresso - Sage Therapeutics
4.5.6 Bizalimogene Ralaplasmid + Mavilimogene Ralaplasmid - Inovio Pharmaceuticals Inc
4.5.7 Retosiban - GlaxoSmithKline

5 Multi-scenario Market Forecast to 2024
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target Class
5.3.1 G Protein-Coupled Receptor
5.3.2 Nuclear Receptor
5.3.3 Pathogen
5.3.4 Ion Channels/Transporter

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Bayer AG - Company to Remain a Market Leader within Women's Health
6.1.2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company's Market Share
6.1.3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
6.1.4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil
6.1.5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6.1.6 Pfizer - How will patent expiration affect revenues for women's health market?
6.1.7 TherapeuticsMD - Women's Health Specialist to Gain Considerable Market Share by 2024
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Value and Year
7.1.2 Deals by Key Indication
7.1.3 Deals by Stage of Development and Value
7.1.4 Deals by Molecule Type, Molecular Target and Value
7.1.5 Licensing Deals with Disclosed Values
7.2 Co-development Deals
7.2.1 Deals by Region, Value and Year
7.2.2 Deals by Key Indication
7.2.3 Deals by Stage of Development and Value
7.2.4 Deals by Molecule Type, Molecular Target and Value
7.2.5 Co-development Deals with Disclosed Values

8 Appendix
8.1 References
8.2 Abbreviations
8.3 List of All Pipeline Products
8.4 Disease List
8.5 Methodology

For more information about this report visit https://www.researchandmarkets.com/research/4c2czn/global_womens?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 05:10
Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions. These devices could be anything from equipment that helps stimulate the nervous system to...

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...



News published on and distributed by: